Alzheimer's Disease Trial, Recruiting NCT05980052 Sponsor: Arizona State University Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT05980052
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between the ages of 45 and 65 years old
  • People with a body mass index (a measure of body weight relative to height) between 30 and 50
  • People who weigh at least 110 pounds
  • People who currently do 60 minutes or less of moderate-to-vigorous physical activity per week, based on a short questionnaire at screening
  • People who own a smartphone that runs iOS (Apple) or Android software, as this is needed to track activity using a Fitbit device provided by the trial

Who may not be able to join:

  • People who answer "yes" to any question on a standard physical activity health-readiness questionnaire, unless a doctor's note is provided
  • People whose resting blood pressure is higher than 200/110 mmHg at their first study visit, unless a doctor's note is provided
  • People who are pregnant or planning to become pregnant within the next 8 months (Phase 1) or 12 months (Phase 2)
  • People who plan to move away from the metropolitan Phoenix, Arizona area within the next 8 months (Phase 1) or 12 months (Phase 2)
  • People who are currently enrolled in, or plan to join, another physical activity, nutrition, or weight loss program during the study period
  • People who have been diagnosed with mild cognitive impairment (a condition affecting memory and thinking), or who score below a certain threshold on a memory and thinking test given at the study orientation session (confirm with trial site for exact score thresholds, which vary based on country of birth and language of schooling)
  • People who have previously been prescribed any of the following Alzheimer's medications: Donepezil (Aricept), Rivastigmine (Exelon), Galantamine (Razadyne), Memantine (Namenda), or a combination of Memantine and Donepezil (Namzaric)
  • People who score 16 or higher on a standard depression symptom questionnaire (the CES-D scale)
  • People who have a current self-reported diagnosis of major depression
  • People who are currently taking two or more antidepressant medications
  • People who have had a stroke at any point in the past
  • People who are currently incarcerated

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 602-496-0772

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Arizona State University
Registry
ClinicalTrials.gov
Start date
17 July 2023
Est. completion
31 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in accelerometer-measured moderate-to-vigorous intensity physical activity from baseline to 6- and 9-months; Change in Fitbit-assessed moderate-to-vigorous intensity physical activity; Change in self-reported moderate-to-vigorous intensity physical activity from baseline to 6- and 9-months

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov